Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model.

[1]  G. Painter,et al.  Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. , 2003, Antiviral research.

[2]  K. Hostetler,et al.  Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. , 2003, Molecular pharmacology.

[3]  M. Bray,et al.  Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections , 2003, Antiviral research.

[4]  E. Kern,et al.  In vitro activity of potential anti-poxvirus agents , 2003, Antiviral research.

[5]  K. Hostetler,et al.  Alkoxyalkyl Esters of Cidofovir and Cyclic Cidofovir Exhibit Multiple-Log Enhancement of Antiviral Activity against Cytomegalovirus and Herpesvirus Replication In Vitro , 2002, Antimicrobial Agents and Chemotherapy.

[6]  K. Hostetler,et al.  Enhanced Inhibition of Orthopoxvirus Replication In Vitro by Alkoxyalkyl Esters of Cidofovir and Cyclic Cidofovir , 2002, Antimicrobial Agents and Chemotherapy.

[7]  M. Bray,et al.  Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir , 2001, Antiviral research.

[8]  D. Smee,et al.  Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. , 2001, Antiviral research.

[9]  P. Earl,et al.  Overview of the vaccinia virus expression system. , 2001, Current protocols in protein science.

[10]  D. Smee,et al.  Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir. , 2000, Antiviral research.

[11]  D. Smee,et al.  Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. , 2000, The Journal of infectious diseases.

[12]  E. De Clercq.  Acyclic nucleoside phosphonates: a new dimension to the chemotherapy of DNA virus and retrovirus infections. , 1998, Journal of medical microbiology.

[13]  K. Hostetler,et al.  Enhanced oral absorption and antiviral activity of 1-O-octadecyl-sn-glycero-3-phospho-acyclovir and related compounds in hepatitis B virus infection, in vitro. , 1997, Biochemical pharmacology.

[14]  M. Wachsman,et al.  Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects. , 1996, Antiviral research.

[15]  M. Connelly,et al.  Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates. , 1995, Molecular pharmacology.

[16]  J. Neyts,et al.  Efficacy of (S)‐1‐(3‐hydroxy‐2‐phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice , 1993, Journal of medical virology.

[17]  M. Connelly,et al.  Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells. , 1993, Biochemical pharmacology.

[18]  D. Spehner,et al.  Restricted replication of ectromelia virus in cell culture correlates with mutations in virus-encoded host range gene. , 1992, Virology.

[19]  R. Buller,et al.  Poxvirus pathogenesis. , 1991, Microbiological reviews.

[20]  F. Fenner.  Smallpox and its eradication , 1988 .

[21]  E. De Clercq,et al.  Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. , 1987, Antiviral research.

[22]  Wallace Gd,et al.  Kinetics of ectromelia virus (mousepox) transmission and clinical response in C57BL/6j, BALB/cByj and AKR/J inbred mice. , 1985 .

[23]  R. Buller,et al.  Kinetics of ectromelia virus (mousepox) transmission and clinical response in C57BL/6j, BALB/cByj and AKR/J inbred mice. , 1985, Laboratory animal science.

[24]  R. Scow,et al.  Incorporation of dietary lecithin and lysolecithin into lymph chylomicrons in the rat. , 1967, The Journal of biological chemistry.

[25]  A. C. Guyton,et al.  Measurement of the respiratory volumes of laboratory animals. , 1947, The American journal of physiology.